Juries have gotten more discerning over the years, with some practitioners claiming an anti-corporate bias among certain populations. Life sciences IP litigation adds a layer of concern to the complex and often confusing subject matter whose nuances are central to the case.
With growing pressure on big pharma and life sciences companies, the complexity of the material being presented, and upwards of millions of dollars hanging in the balance, ensuring a properly arranged jury could be make or break to the success of your case.
At the Pharma & Biotech Patent Litigation USA & Canada Conference, the Hon. Judge Jose L. Linares (Ret.) joins fellow speakers for a discussion on jury selection strategies in complex pharmaceutical and biotechnology patent disputes. The session explores how litigators can identify potential juror biases during voir dire, including anti-corporate sentiment, hindsight bias, “safetyism,” and medical skepticism, while working to ensure a fair and balanced jury. Speakers also examine effective approaches for evaluating jurors’ ability to understand complex scientific and technical evidence, including considerations such as educational background, professional experience, and comprehension of the juror’s role in assessing a case on its merits.